Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

Prof Stéphane Kremer*, MD - François Lersy*, MD - Prof Jérôme de Sèze, MD - Prof Jean-Christophe Ferré, MD - Adel Maamar, MD - Béatrice Carsin-Nicol, MD - Prof Olivier Collange, MD - Prof Fabrice Bonneville, MD - Gilles Adam, MD - Prof Guillaume Martin-Blondel, MD - Marie Rafiq, MD - Prof Thomas Geeraerts, MD - Louis Delamarre, MD - Sylvie Grand, MD - Prof Alexandre Krainik, MD - Prof Sophie Caillard, MD, - Prof Jean Marc Constans, MD - Serge Metanbou, MD - Adrien Heintz, PhD - Prof Julie Helms, MD - Maleka Schenck, MD - Nicolas Lefèbre, MD - Prof Claire Boutet, MD - Xavier Fabre, MD - Géraud Forestier, MD - Iasaure de Beaurepaire, MD - Grégoire Boulorn, MD - Audrey Lacalm, MD - Hélène Oesterlé, MD - Federico Bolognini, MD - Julien Messie, MD - Ghazi Hmeydia, MD - Joseph Benazkoun, MD - Prof Catherine Oppenheim, MD - Blanche Bapst, MD - Imen Megdiche, MD - Marie-Cécile Henri-Feugeas, MD - Prof Antoine Khalil, MD - Augustin Gaudemer, MD - Lavinia Jager, MD - Patrick Nesser, MD - Yannick Tallal Mba, MD - Céline Hemmert, MD, - Philippe Feuerstein, MD - Nathan Sebag, MD - Sophie Carré, MD - Manel Alleg, MD - Claire Lecocq, MD - Emmanuelle Schmitt, MD - Prof René Anxionnat, MD - François Zhu, MD - Pierre-Olivier Comby, MD - Prof Frédéric Ricolli, MD - Pierre Thouant, MD - Prof Hubert Desal, MD - Grégoire Boulouis, MD - Jérome Berge, MD - Apolline Kazémi, MD - Nadya Pyatigorskaya, MD - Augustin Leclerc, MD - Suzana Saleme, MD - Myriam Edjlali-Goujon, MD - Basile Kerleroux, MD - Pierre-Emmanuel Zorn, PhD - Muriel Mathieu - Seyyid Baloglu, MD - François-Daniel Ardellier, MD - Thibault Willaume, MD - Jean Christophe Brisset, PhD - Clotilde Boulay, MD - Véronique Mutschler, MD - Prof Yves Hansmann, MD - Prof Paul-Michel Mertes, MD - Prof Francis Schneider, MD - Prof Samira Fafi-Kremer, PharmD - Prof Mickael Ohana, MD - Prof Ferhat Meziani, MD - Prof Jean-Stéphane David, MD - Prof Nicolas Meyer, MD - Prof Mathieu Anheim, MD - Pr François Cotton, MD

*S.K. and F.L. contributed equally to the work.

Contributions:
SK, FC, FL, JDS, and MA were responsible for the conception of the study. SK, FC, FL, JDS and MA collected the epidemiological, clinical, laboratory, and radiological data, and had full access to all data in the study and take responsibility for the accuracy of the data analysis. NM contributed to the statistical analysis. SK, FC, FL, JDS, and MA contributed to the writing and revision of the present report.
All other authors contributed to the acquisition, analysis, or interpretation of data, and revised and approved the final manuscript.

Corresponding author:
Stéphane Kremer, Hôpitaux Universitaires de Strasbourg, Service d’imagerie 2, Hôpital de Hautepierre, 1 avenue Molière 67200 Strasbourg, France (email: stephane.kremer@chru-strasbourg.fr)

Author list and affiliations:
Stéphane Kremer (MD, PhD) (1,2)*, François Lersy (MD) (1)*, Jérôme de Sèze (MD, PhD) (3), Jean-Christophe Ferré (MD, PhD) (4), Adel Maamar (MD) (5), Béatrice Carsin-Nicol (MD) (4), Olivier Collange (MD, PhD) (6), Fabrice Bonneville (MD, PhD) (7), Gilles Adam (MD) (7), Guillaume Martin-Blondel (MD, PhD) (8), Marie Rafiq (MD) (9), Thomas Geeraerts (MD, PhD) (10), Louis Delamarre (MD) (10), Sylvie Grand (MD) (11), Alexandre Krainik (MD, PhD) (11), Sophie Caillard (MD, PhD) (12), Jean Marc Constans (MD, PhD) (13), Serge Metanbou (MD) (14), Adrien Heintz (PhD) (13), Julie Helms (MD, PhD) (15,16), Maleka Schenck (MD) (17), Nicolas Lefèbre (MD) (18), Claire Boutet (MD, PhD) (19), Xavier Fabre (MD) (20), Géraud Forestier (MD) (21), Iasaure de Beaurepaire (MD) (22), Grégoire Boulorn (MD) (22), Audrey Lacalm (MD) (23), Hélène Oesterlé (MD) (24), Federico Bolognini (MD) (24), Julien Messie (MD) (24), Ghazi Hmeydia (MD) (25), Joseph Benazkoun (MD) (25), Catherine Oppenheim (MD, PhD) (25), Blanche Bapst (MD) (26), Imen Megdiche (MD) (26), Marie-Cécile Henri-Feugeas (MD, PhD) (27), Antoine Khalil (MD) (28), Augustin Gaudemer (MD) (27), Lavinia Jager (MD) (29), Patrick Nesser (MD) (29), Yannick Tallal Mba (MD) (29), Céline Hemmert (MD) (30), Philippe Feuerstein (MD) (30), Nathan Sebag (MD) (30), Sophie Carré (MD) (31), Manel Alleg (MD) (32), Claire Lecocq (MD) (31), Emmanuelle Schmitt (MD) (33), René Anxionnat (MD, PhD) (33), François Zhu (MD) (33), Pierre-Olivier Comby (MD) (34), Frédéric Ricolli (MD, PhD) (34), Pierre Thouant (MD) (34), Hubert Desal (MD, PhD) (35), Grégoire Boulouis (MD) (35), Jérome Berge (MD) (36), Apolline Kazémi (MD) (37), Nadya Pyatigorskaya (MD, PhD) (38), Augustin Leclerc (MD, PhD) (39), Suzana Saleme (MD) (21), Myriam Edjlali-Goujon (MD, PhD) (25), Basile Kerleroux (MD) (25), Pierre-Emmanuel Zorn (PhD) (40), Muriel Mathieu (40), Seyyid Baloglu (MD) (1), François-Daniel Ardellier (MD) (1), Thibault Willaume (MD) (1), Jean Christophe Brisset (PhD) (41), Clotilde Boulay (MD) (3), Véronique Mutschler (MD) (3), Yves Hansmann (MD, PhD), (18), Paul-Michel Mertes (MD, PhD)
PhD) (6), Francis Schneider (MD, PhD) (17), Samira Fafi-Kremer (PharmD, PhD) (42), Mickael Ohana (MD, PhD) (43), Ferhat Meziani (15,44), Jean-Stéphane David (MD, PhD) (45), Nicolas Meyer (MD, PhD) (46), Mathieu Anheim (MD, PhD) (3,47), François Cotton (MD, PhD) (48,49)

* S.K. and F.L. contributed equally to the work.

1. Hôpitaux Universitaires de Strasbourg, Service d’imagerie 2, Hôpital de Hautepierre, Strasbourg, France
2. Engineering science, computer science and imaging laboratory (ICube), Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg-CNRS, Strasbourg, France
3. Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
4. CHU Rennes, Department of Neuroradiology, Rennes, France
5. Service de maladies infectieuses et réanimation médicale. CHU Rennes, France
6. Hôpitaux universitaires de Strasbourg, Service d’Anesthésie-Réanimation, Nouvel Hôpital Civil, Strasbourg, France
7. Service de Neuroradiologie, CHU Toulouse, Toulouse, France.
8. Department of infectious and tropical diseases, Toulouse University Hospital, Toulouse, France
9. Department of Neurology, Toulouse University Hospital, Toulouse, France.
10. Department of Anesthesia and Critical Care, Toulouse University Hospital University Toulouse 3-Paul Sabatier, Toulouse, France
11. Service de neuroradiologie diagnostique et interventionnelle, Centre Hospitalier Universitaire des Alpes, Grenoble, France
12. Nephrology and Transplantation department, Hôpitaux Universitaires de Strasbourg. Inserm UMR S1109, LabEx Transplantex, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
13. EA CHIMERE 7516, Université de Picardie Jules Verne, Amiens, France ; Service de NeuroRadiologie, pôle Imagerie Médicale, Centre Hospitalo-Universitaire d'Amiens, Amiens, France
14. Service de Neuro Radiologie, pôle Imagerie Médicale, Centre Hospitalo-Universitaire d'Amiens, Amiens, France
15. Hôpitaux universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Strasbourg, France
16. Immuno-Rhumatologie Moléculaire, INSERM UMR S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France
17. Hôpitaux universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Hautepierre, Strasbourg, France
18. Service de Maladies infectieuses, NHC, CHU de Strasbourg, Strasbourg, France
19. Service de Radiologie, CHU de Saint-Etienne, Saint-Etienne, France
20. Service de Réanimation, CH de Roanne, Roanne, France
21. University Hospital of Limoges, Neuroradiology Department, Limoges, France
22. Radiology Department, Hôpital Privé d’Antony, Antony, France
23. Service d’imagerie Pédiatrique et Fœtale, Hôpital Femme Mère Enfant, HCL, Lyon, France
24. Service de Neuroradiologie, Hôpitaux Civils de Colmar, Colmar, France
25. INSERM U1266, Service d’imagerie morphologique et fonctionnelle, GHU Psychiatrie et Neurosciences, site Sainte-Anne, Paris, France
26. service de Neuroradiologie, CHU Henri Mondor, Créteil, France
27. Neuroradiology Unit, Department of Radiology, Assistance Publique–Hôpitaux de Paris (APHP), Bichat University Hospital, Paris, France
28. Department of Radiology, Assistance Publique–Hôpitaux de Paris (APHP), Denis Diderot University and Medical School, Bichat University Hospital, Paris, France
29. CHIC Unisanté, Hôpital Marie Madeleine, Forbach, France
30. service de Radiologie 1, GHR Mulhouse Sud Alsace, Hôpital Mère Enfants, Mulhouse, France
31. Service de Neurologie, Centre Hospitalier de Haguenau, Haguenau, France
32. Service de Radiologie, Centre Hospitalier de Haguenau, Haguenau, France
33. Service de Neuroradiologie, Hôpital Central, CHU de Nancy, Nancy, France
34. Department of Neuroradiology, University Hospital of Dijon, Hôpital François Mitterrand, Dijon, France
35. Department of Diagnostic and Interventional Neuroradiology, University Hospital, Nantes, France
36. Neuroradiology department - CHU de Bordeaux, Bordeaux, France
37. Service de Neuroradiologie, CHU de Lille, Lille, France
38. Assistance Publique Hôpitaux de Paris, Service de Neuroradiologie, Hôpital Pitié-Salpêtrière, Paris, France Sorbonne Université, Univ Paris 06, UMR S 1127, CNRS UMR 7225, ICM, F-75013, Paris, France
Summary Statement

Eight distinctive neuroradiologic patterns (excluding ischemic infarcts) were identified in patients with severe COVID-19 infection with abnormal brain MRIs.

Key Results

1. In patients with COVID-19, the most frequent neuroimaging features were: involvement of the medial temporal lobe, non-confluent multifocal white matter hyperintense lesions on FLAIR with variable enhancement and hemorrhagic lesions, and extensive and isolated white matter microhemorrhages.

2. A majority of our patients presented intracerebral hemorrhagic lesions, which were associated with worse clinical status.

3. Of 37 patients, only one was positive for SARS-CoV-2 RNA in the cerebrospinal fluid.

Abbreviations

ADEM: Acute disseminated encephalomyelitis
ANE: Acute necrotizing encephalopathy
ARDS: Acute respiratory distress syndrome
CNS: Central nervous system
CoV: Coronavirus
CSF: Cerebrospinal fluid
EEG: Electroencephalogram
FLAIR: Fluid-attenuated inversion recovery
HCoV: Human coronavirus
ICU: Intensive care unit
PRES: Posterior reversible encephalopathy syndrome
RT-PCR: Reverse transcriptase-polymerase chain reaction
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
WM: White matter

Abstract
Background
Brain MRI parenchymal signal abnormalities have been in association with SARS-CoV-2.

Purpose
Describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe COVID-19 infection.

Methods
This was a retrospective study of patients evaluated from March 23rd, 2020 to April 27th, 2020 at 16 hospitals. Inclusion criteria were: (i) positive nasopharyngeal or lower respiratory tract reverse transcriptase-polymerase chain reaction assays; (ii) severe COVID infection defined as requirement for hospitalization and oxygen therapy; (iii) neurologic manifestations; (iv) abnormal brain MRI. Exclusion criteria were patients with missing or non-contributory data regarding brain MRI or a brain MRI showing ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event. Categorical data were compared using Fisher exact test. Quantitative data were compared using Student’s t-test or Wilcoxon test. A p-value lower than 0.05 was considered significant.

Results
Thirty men (81%) and 7 women (19%) met inclusion criteria, with a mean age of 61 +/- 12 years (range: 8-78). The most common neurologic manifestations were alteration of consciousness (27/37, 73%), pathological wakefulness when the sedation was stopped (15/37, 41%), confusion (12/37, 32%), and agitation (7/37, 19%). The most frequent MRI findings were: signal abnormalities located in the medial temporal lobe in 16/37 (43%, 95% CI 27-59%) patients, non-confluent multifocal white matter hyperintense lesions on FLAIR and diffusion sequences, with variable enhancement, with associated hemorrhagic lesions in 11/37 patients (30%, 95% CI 15-45%), and extensive and isolated white matter microhemorrhages in 9/37 patients (24%, 95% CI 10-38%). A majority of patients (20/37, 54%) had intracerebral hemorrhagic lesions with a more severe clinical presentation: higher admission rate in intensive care units, 20/20 patients, 100% versus 12/17 patients, 71%, p=0.01; development of the acute respiratory distress syndrome in 20/20 patients, 100% versus 11/17 patients, 65%, p=0.005. Only one patient was positive for SARS-CoV-2 RNA in the cerebrospinal fluid.

Conclusion
Patients with severe COVID-19 and without ischemic infarcts had a wide range of neurologic manifestations that were be associated with abnormal brain MRIs. Eight distinctive neuroradiological patterns were described.

Introduction
SARS-CoV-2 is the seventh member of the family of coronaviruses (CoVs) that infect humans (1) and induces COVID-19 disease. Human CoVs (HCoVs) have neuroinvasive capacities and may be neurovirulent by two main mechanisms (2-4): viral replication into glial or neuronal cells of the brain, or autoimmune reaction with a misdirected host immune response (5). Thus, a few cases of acute encephalitis-like syndromes with hCoVs were reported in the past two decades (5-8). Concerning COVID-19, current data on central nervous system (CNS) involvement is uncommon but growing (9-17), demonstrating the high frequency of neurological symptoms.

However, the delineation of a large cohort of confirmed brain MRI parenchymal signal abnormalities (excluding ischemic infarcts) related to COVID-19 has never been performed, and the underlying pathophysiological mechanisms remain unknown. The purpose of this current study was to describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe COVID-19 and report the clinico-biological profile of these patients.

Material & Methods

This retrospective observational national multicenter study was initiated by the French Society of Neuroradiology (SFNR) in collaboration with neurologists, intensivists, and infectious disease specialists, and brought together 16 hospitals. The study was approved by the ethical committee of Strasbourg University Hospital (CE-2020-37) and was in accordance with the 1964 Helsinki Declaration and its later amendments. Due to the emergency in the context of COVID-19 pandemic responsible for acute respiratory and neurological manifestations pandemic, the requirement for patients’ written informed consent was waived.

Patient cohort

Consecutive patients with COVID-19 infection and neurologic manifestations who underwent brain MRI were included from March 23th, 2020, to April 27th, 2020, in 16 French centers, including 11 university hospitals and 5 general hospitals. Inclusion criteria were: (i) diagnosis of COVID-19 based on possible exposure history or symptoms clinically compatible, validated with a detection of SARS-CoV-2 by reverse transcriptase-polymerase chain reaction (RT-PCR) assays on the nasopharyngeal, throat or lower respiratory tract swabs; (ii) severe COVID-19 infection defined as requirement for hospitalization and oxygen therapy; (iii) neurologic manifestations; (iv) abnormal brain MRI with acute/subacute abnormalities. Exclusion criteria were: (i) patients with missing or non-contributory data (lack of sequences, numerous artifacts) regarding brain MRI; (ii) a brain MRI showing ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event.

Clinical and laboratory data were extracted from the patients’ electronic medical records in the Hospital Information System. Only laboratory analysis within three days before the brain MRI were considered. In the case of redundancy of the tests, the worst value has been kept. Clinical and biological data were reviewed by two neurologists (J.D.S., and M.A. with 25 and 15 years of clinical expertise on neurology, respectively), and by one virologist (S.F-K). They participated to the elaboration of the study design, the interpretation of the data, and to manuscript editing. When available, all electroencephalogram (EEG) were reviewed by one expert neurologist (C.B.) and classified into five groups (normal, under sedation, nonspecific, encephalopathy or seizures).

Virological assessment

Quantitative real-time RT-PCR tests for SARS-CoV-2 nucleic acid were performed on nasopharyngeal or lower respiratory tract swabs, and cerebrospinal fluid (CSF). Primer and probe sequences target two regions on the RdRp gene and are specific to SARS-CoV-2. Assay sensitivity is around 10 copies/reaction (in house-method, Institut Pasteur, Paris, France) (18).

Brain MRI protocols

Imaging studies were conducted either on 1.5- or 3-Tesla MRI. The multicenter nature of the study and the various clinical setups did not allow standardization of sequences. The most frequently sequences performed were 3D TI-weighted spin-echo MRI with and without contrast enhancement, diffusion-weighted imaging (DWI), gradient-echo T2 or Susceptibility-weighted imaging, and 2D or 3D FLAIR after administration of gadolinium-based contrast agent.

MRI interpretation

After anonymization, images were presented to readers with our GE Picture Archiving and Communication System (General Electric, Milwaukee, WI, USA). After review of MRI studies by three neuroradiologists (S.K., F.C., and F.L. with 20, 25, and 9 years of experience in neuroradiology, respectively) who were blinded to all patient data, brain MRI findings were divided by consensus into eight groups: (a) unilateral FLAIR and/or diffusion hyperintensities located in medial temporal lobe; (b) FLAIR and diffusion ovoid hyperintense lesion located in the central part of the splenium of the corpus callosum; (c) non-confluent multilobar white matter (WM) hyperintense lesions on FLAIR and diffusion, with variable enhancement; (d) non-confluent multilobar WM hyperintense lesions on FLAIR and diffusion, with...
variable enhancement, associated with hemorrhagic lesions; (e) acute necrotizing encephalopathy (ANE) (9) when symmetric thalamic lesions (edema, petechial hemorrhage, and necrosis), with variable involvement of the brainstem, internal capsule, putamen, cerebral and cerebellar WM; (f) extensive and isolated WM microhemorrhages; (g) extensive and confluent supratentorial WM FLAIR hyperintensities; (h) FLAIR hyperintense lesions involving both middle cerebellar peduncles. Patients could have had more than one pattern.

Statistical analysis
Data were described using frequency and proportion (n, %) for categorical variables, using mean, median, interquartile range, and range for quantitative data. In a second step, patients with hemorrhagic lesions were gathered into a single group called « patients with hemorrhagic complications », to look for clinico-biological differences between the two populations. Categorical data were compared using Fisher exact test. Quantitative data were compared using Student’s t-test or Wilcoxon test. A p-value lower than 0.05 was considered significant.

Results
Between March 23th, 2020, and April 27th, 2020, 190 consecutive patients with COVID-19 infection and neurologic manifestations, performed a brain MRI in 16 hospitals. Among them, were excluded all patients with normal brain MRI, ischemic infarcts, cerebral venous thrombosis or chronic lesions unrelated to the current event. A total of 37 patients with COVID-19 infection were finally included in this study (figure 1). The average age of the patients was 61 +/- 12 years with 30 men and 7 women included (table 1). The majority of our patients (32/37, 87%) were admitted to Intensive Care Units (ICUs) because of acute respiratory failure. The most frequent neurologic manifestations were alteration of consciousness (27/37, 73%), pathological wakefulness after sedation (15/37, 41%), confusion (12/37, 32%), and agitation (7/37, 19%).

Among the 26 EEG performed, 2 (8%) were considered as normal, 6 (23%) were realized under sedation, 10 (39%) showed nonspecific findings, 7 (27%) were classified as encephalopathy, and 1 (4%) case of seizures was also described. At the end of the study, the mortality rate was 14%. The blood counts of patients showed leukocytosis, lymphopenia, and anemia. Patients had elevated serum levels of C-reactive protein, ferritin, alanine aminotransferase, aspartate aminotransferase, urea, creatinine, fibrinogen, and D-dimers (table 2). Fifteen out of the 19 patients (79%) studied for the presence of a lupus anticoagulant were positive.

Thirty-one patients underwent a lumbar puncture, and among them, 21/31(68%) had increased markers of inflammation (high white blood cell count, and/or high proteinorachia, and/or elevated immunoglobulin G). One patient demonstrated the presence of SARS-CoV-2 on RT-PCR. High levels of interleukin-6 were found in 2 out of 6 patients (table 3).

Neuroimaging findings
The results of MRI findings are summarized in figure 1. Among the 37 patients included, 28/37 (76%) were associated with one neuroimaging pattern, 7/37 (19%) with two patterns, and 2/37 (5%) showed three patterns (figures 1-6). The most frequent neuroimaging findings were: signal abnormalities located in the medial temporal lobe in 16/37 (43%, 95%IC 27-59%) patients (figure 2), non-confluent multifocal WM hyperintense lesions on FLAIR and diffusion, with variable enhancement, associated with hemorrhagic lesions in 11/37 (30%, 95%IC 15-45%) patients (figure 3), and in 9/37 (24%, 95%IC 10-38%) patients extensive and isolated WM microhemorrhages were detected (figure 4).

Comparison of patient groups with and without hemorrhagic lesions
The comparison between patients with and without intracerebral hemorrhagic lesions shows that the hemorrhagic complications were more frequently associated with ICU admission (20/20, 100% versus 12/17, 71%, p=0.01), with acute respiratory distress syndrome (ARDS) (20/20, 100% versus 11/17, 65%, p=0.005) and with pathological wakefulness when sedative therapies were stopped (13/20, 65% versus 2/17, 12%, p=0.002). The time between the onset of symptoms (most often respiratory) to brain MRI was longer for patients with intracerebral hemorrhagic lesions (mean duration of 33 days versus 19 days, p<0.001). Leukocytosis (median of 13.4 x 10^9/L versus 10.4 x 10^9/L, p=0.03), anemia (median of 87 g/L versus 110 g/L, p<0.001), and renal dysfunction (urea’s median of 18mmol/L versus 7mmol/L, p=0.026) were more pronounced in the case of hemorrhagic lesions.

Discussion
Among the eight groups of brain MRI features classification, three main neuroradiological patterns appeared more frequently in patient with severe COVID-19: signal abnormalities located in the medial temporal lobe, non-confluent multifocal WM hyperintense lesions on FLAIR and diffusion with variable enhancement, associated with hemorrhagic lesions, and extensive and isolated WM microhemorrhages. The presence of hemorrhage was frequent, and the detection is of clinical importance as it was associated with worse respiratory, neurological, and biological status.
Nevertheless, the underlying mechanism of brain abnormalities remains unsolved, and the direct implication of SARS-CoV-2 is not clear as only one patient was positive for SARS-CoV-2 RNA in the CSF.

Unilateral FLAIR and/or diffusion hyperintensities located in medial temporal lobe were frequent and have been previously reported in one patient with COVID-19 (10). The latter is frequently observed in case of infectious encephalitis (especially with some viruses like Herpes simplex virus, Human herpesvirus 6, or Epstein-Barr virus) or in association with autoimmune limbic encephalitis (19).

Non-confluent multifocal WM hyperintense lesions on FLAIR and diffusion, with variable enhancement, which could be associated with hemorrhagic lesions, have rarely been reported in patients with COVID-19 (20). The latter presentation is close to what can be observed on brain MRIs in case of an inflammatory demyelinating disease such as acute disseminated encephalomyelitis (ADEM) or acute hemorrhagic leukoencephalitis. However, these two latter diagnoses cannot only be retained on the radiological presentation without the typical CSF analysis or clinical presentation (21,22). Several putative mechanisms underlying neurological consequences of COVID-19 are evoked and among them immunological parainfectious processes (23). The immunologic assumption is also reinforced by a recent neuropathological study which described ADEM-like lesions in the subcortical WM in a patient with severe COVID-19 (24).

Extensive and isolated WM microhemorrhages pattern was recently described in 7 critically ill patients with COVID-19 (12) and in the neuropathology study above mentioned (24). A similar pattern was recently described in one case (25) with disseminated intravascular coagulation. However, according to the criteria endorsed by the International Society on Thrombosis and Haemostasis (27), when they were available, no case of disseminated intravascular coagulation was present in our cohort. Its precise pathophysiology remains uncertain and will require further studies. Radmanesh et al. (12) evoking the assumptions of hypoxia or small vessel vasculitis.

A small number of patients presented extensive and confluent supratentorial WM FLAIR hyperintensities (figure 2), as previously described by Kandemirli et al. (11) and Radmanesh et al. (12). Its precise pathophysiology remains unclear: viral encephalitis (not supported by CSF analysis) or post-infectious demyelinating diseases, as previously mentioned, may be evoked. Since most of our patients were admitted to ICUs for an ARDS, more general assumptions may be considered, such as delayed post-hypoxic leukoencephalopathy (27), metabolic or toxic encephalopathy, and posterior reversible encephalopathy syndrome (PRES). This last hypothesis is in accordance with recently published non-hemorrhagic and hemorrhagic PRES in patients with COVID-19 (28).

Even if this national neuroimaging cohort remains unique, our study has several limitations, mainly due to his retrospective design. The main limitation is that certain laboratory data were missing for some patients, notably the immunological tests. Moreover, patients’ outcomes were not always known at the time of this communication. Thus, the mortality rate is probably underestimated in our cohort.

In conclusion, in this multi-institutional study, we report 37 patients with COVID-19 and abnormal brain MRIs (excluding ischemic infarcts). Three main neuroradiological patterns could be distinguished, and the presence of hemorrhage was associated with worse clinical status. SARS-CoV-2 RNA was detected in the CSF only in one patient, and the underlying mechanisms of brain involvement remain unclear. Imaging and neurological follow up has to be undertaken in order to evaluate the prognosis of these patients.

**Conflicts of interest**

All authors declare no competing interests.

**References**
1) Na Zhu, Dingyu Zhang, Wenling Wang, et al. A Novel Coronavirus From Patients With Pneumonia in China, 2019.N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017.

2) Bohnwald K, Gálvez NMS, Rios M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections. Front Cell Neurosci. 2018;12:386. Published 2018 Oct 26. doi:10.3389/fncel.2018.00386

3) Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res. 2014 Dec 19;194:145-58. doi: 10.1016/j.viruses.2014.09.011.

4) Desforges M, Le Coupanec A, Dubeau P, et al. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses. 2019 Dec 20;12(1). pii: E14. doi:10.3390/v12010014.

5) Li Y, Li H, Fan R, et al. Coronavirus Infections in the Central Nervous System and Respiratory Tract Show Distinct Features in Hospitalized Children. Intervirology. 2016;59(3):163-169. doi:10.1159/000453066.

6) Arabi YM, Harthi A, Hussein J, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection. 2015 Aug;43(4):495-501. doi: 10.1007/s15010-015-0720-y.

7) Kim JE, Heo JH, Kim HO, et al. Neurological Complications during Treatment of Middle East Respiratory Syndrome. J Clin Neurol. 2017 Jul;13(3):227-233. doi: 10.3988/jcn.2017.13.3.227.

8) Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics. 2004 Jan;113(1 Pt 1):e73-6.

9) Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features. Radiology. 2020 Mar 31;201187. doi: 10.1148/radiol.2020201187.

10) Moriguchi T, Harii N, Goto J, et al. A first Case of Meningitis/Encephalitis associated with SARS-CoV-2. Int J Infect Dis. 2020 Apr 3. pii: S1201-9712(20)30195-8. doi: 10.1016/j.ijid.2020.03.062.

11) Kandemirli SG, Dogan L, Sarıkaya ZT, et al. Brain MRI Findings in Patients in the Intensive Care Unit with COVID-19 Infection. Radiology. 2020 May 8;201697. doi: 10.1148/radiol.radiol.2020201697.

12) Radmanesh A, Derman A, Lui YW, et al. COVID-19 -associated Diffuse Leukoencephalopathy and Microhemorrhages [published online ahead of print, 2020 May 21]. Radiology. 2020;202040. doi:10.1148/radiol.20202040.

13) Franceschi AM, Ahmed O, Giliberto L, Castillo M. Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection [published ahead of print, 2020 May 21]. AJNR Am J Neuroradiol. 2020;31:174-175. doi:10.3174/ajnr.A6595.

14) Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 Apr 10. doi: 10.1001/jamaneurol.2020.1127.

15) Mahammedi A, Saba L, Vagal A, et al. Imaging in Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Retrospective Observational Study [published online ahead of print, 2020 May 21]. Radiology. 2020;2020193. doi:10.1148/radiol.2020201933.

16) Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020 Apr 15. doi: 10.1056/NEJMoa2005897.

17) Romero-Sánchez CM, Díaz-Maroto I, Fernández-Diaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry [published online ahead of print, 2020 Jun 1]. Neurology. 2020;10.1212/0052197293.

18) World Health Organization. Protocol: Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut Pasteur, World Health Organization. https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2

19) Badhram A, Leung A, Nicolle MW, Burneo JG. Diagnosing autoimmune limbic encephalitis. CMAJ. 2019 May 13;191(19):E529-E534. doi: 10.1503/cmaj.181548.

20) Parsons T, Banks S, Bae C, Gelber J, Alahmadi H, Tichauer M. COVID-19-associated acute disseminated encephalomyelitis (ADEM) [published online ahead of print, 2020 May 30]. J Neurol. 2020;1-4. doi:10.1159/000453066-9.

21) Pohl D, Alper G, Van Haren K, et al. Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology. 2016 Aug 30;87(Suppl 2):S38-45. doi: 10.1212/WNL.0000000000002825.

22) Nabi S, Badshah M, Ahmed S, Nomani AZ. Weston-Hurst syndrome: a rare fulminant form of acute disseminated encephalomyelitis (ADEM). BMJ Case Rep. 2016 Oct 19;2016. pii: bcr2016217215. doi: 10.1136/bcr-2016-217215.

23) Needham EJ, Chou SH, Coles AJ, Menon DK. Neurological Implications of COVID-19 Infections [published online ahead of print, 2020 Apr 28]. Neurocrit Care. 2020;1-5. doi:10.1007/s12028-020-00978-4.

24) Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology [published online ahead of print, 2020 May 24]. Acta Neuropathol. 2020;10.1007/s00401-020-02166-2. doi:10.1007/s00401-020-02166-2.
25) Radmanesh F, Rodriguez-Pla A, Pincus MD, Burns JD. Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis. J Clin Neurosci. 2020 Apr 16. pii: S0967-5868(20)30681-0. doi: 10.1016/j.jocn.2020.04.054.

26) Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–1330.

27) Katyal N, Narula N, George P, Nattanamai P, Newey CR, Beary JM. Delayed Post-hypoxic Leukoencephalopathy: A Case Series and Review of the Literature. Cureus. 2018;10(4):e2481. Published 2018 Apr 15. doi:10.7759/cureus.2481

28) Kishfy L, Casasola M, Banankhah P, et al. Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19 [published online ahead of print, 2020 May 23]. J Neurol Sci. 2020;414:116943. doi:10.1016/j.jns.2020.116943
Table 1: Epidemiologic profile and clinical characteristics

| Demographic and clinical parameters | All patients (n=37) | Non-hemorrhagic forms (n=17) | Hemorrhagic forms (n=20) | p-value |
|-------------------------------------|---------------------|-----------------------------|-------------------------|---------|
| **Sex (Men / Women)**               | 30 (81%) / 7 (19%)  | 15 (88%) / 2 (12%)          | 15 (75%) / 5 (25%)      | 0.41    |
| **Age (years), mean / range**       | 61 / 8-78           | 58 / 8-73                   | 64 / 51-78              | 0.11    |
| **Time from onset of symptoms* to first hospital admission (days) Mean / Median / Range** | 7 / 7 / 0-30        | 7 / 7 / 0-15                | 8 / 7 / 3-30            | 0.71    |
| **Time from onset of symptoms* to brain MRI (days) Mean / Median / Range** | 27 / 27 / 1-46      | 19 / 21 / 1-32              | 33 / 33 / 21-46         | <0.001  |
| **Oxygen therapy**                  | 36 (97%)            | 16 (94%)                    | 20 (100%)               | 0.45    |
| **Acute respiratory distress syndrome** | 31 (84%)           | 11 (65%)                    | 20 (100%)               | 0.005   |
| **Admitted in intensive care units** | 32 (87%)            | 12 (71%)                    | 20 (100%)               | 0.01    |
| **Death of the patient**            | 5 (14%)             | 1 (6%)                      | 4 (20%)                 | 0.34    |
| **Medical history**                 |                     |                             |                         |         |
| **History of stroke**               | 7 (19%)             | 1 (6%)                      | 6 (30%)                 | 0.09    |
| **History of seizures**             | 1 (3%)              | 1 (6%)                      | 0                       | 0.45    |
| **Another neurological history**    | 8 (22%)             | 5 (29%)                     | 3 (15%)                 | 0.42    |
| **Neurologic manifestations**       |                     |                             |                         |         |
| **Headaches**                       | 4 (11%)             | 3 (18%)                     | 1 (5%)                  | 0.31    |
| **Seizures**                        | 5 (14%)             | 2 (12%)                     | 3 (15%)                 | 1       |
| **Clinical signs of corticospinal tract involvement** | 4 (11%)            | 1 (6%)                      | 3 (15%)                 | 0.6     |
| **Disturbance of consciousness**   | 27 (73%)            | 10 (59%)                    | 17 (85%)                | 0.13    |
| **Confusion**                       | 12 (32%)            | 8 (47%)                     | 4 (20%)                 | 0.15    |
| **Agitation**                       | 7 (19%)             | 5 (29%)                     | 2 (10%)                 | 0.21    |
| **Pathological wakefulness in intensive care units** | 15 (41%)          | 2 (12%)                     | 13 (65%)                | 0.002   |

*most often respiratory
### Table 2: Laboratory findings

| Laboratory findings / data are median (IQR)                  | Normal range                   | All patients (n=37)       | Non-hemorrhagic forms (n=17) | Hemorrhagic forms (n=20) | p-values |
|------------------------------------------------------------|--------------------------------|----------------------------|-------------------------------|--------------------------|----------|
| White blood cell count, $\times 10^9$/L (N=36)              | (4-10)                        | 11.8 (8.2-15)              | 10.4 (7.6-13.7)               | 13.4 (10-19.2)           | 0.03     |
| Lymphocyte count, $\times 10^9$/L (N=36)                    | (1.5-4)                       | 1.09 (0.65-1.5)            | 1.22 (0.52-1.47)              | 1.06 (0.79-1.5)          | 0.8      |
| Haemoglobin, g/L (N=36)                                     | (120-160 Women)               | 97 (87-115)                | 110 (104-123)                 | 87 (82-97)               | $<0.001$ |
|                                                           | (130-180 Men)                 |                            |                               |                          |          |
|                                                           |                                |                            |                               |                          |          |
| Platelet count, $\times 10^9$/L (N=36)                      | (150-450)                     | 292 (194-342)              | 294 (146-324)                 | 284 (205-408)            | 0.65     |
| C-reactive protein, mg/L (N=32)                             | < 4                           | 58.5 (22.8-155)            | 73 (18-172)                   | 44 (23-139)              | 0.85     |
| Ferritin, μg/L (N=24)                                       | (22-322)                      | 1289 (777-2124)            | 1364 (618-1957)               | 1289 (973-3941)          | 0.26     |
| Alanine aminotransferase, U/L (N=34)                        | (9-59)                        | 75 (42-119)                | 70 (45-102)                   | 89 (31-123)              | 0.55     |
| Aspartate aminotransferase, U/L (N=34)                      | (11-34)                       | 48 (33-69)                 | 55 (34-68)                    | 40 (30-72)               | 0.49     |
| Urea, mmol/L (N=35)                                         | (2.5-7)                       | 13 (6.5-22)                | 7 (5.5-12)                    | 18 (12-28)               | 0.026    |
| Creatinine, μmol/L (N=35)                                   | (64-104)                      | 112 (62-221)               | 68 (59-101)                   | 165 (100-247)            | 0.09     |
| Prothrombin time, s (N=30)                                  | (13-14)                       | 14 (13-15)                 | 14 (13-15)                    | 14(13-15)                | 0.5      |
| Fibrinogen, g/L (N=32)                                      | (2-4)                         | 6.9 (5.5-8.4)              | 8.2 (7-9.3)                   | 6.4 (5.2-8)              | 0.06     |
| D-dimers, mg/L (N=28)                                       | < 0.5                         | 2.9 (1.5-3.9)              | 1.7 (0.7-3.5)                 | 3.4 (2.3-4)              | 0.08     |
| **Immunological tests: data are n/N (%)**                   |                               |                            |                               |                          |          |
| Lupus anticoagulant (N=19)                                  | _                             | 15/19 (79%)                | 5/6 (83%)                     | 10/13 (77%)              | 1        |
| Other antiphospholipid antibody (N=8)                       | _                             | 4/8 (50%)                  | 2/3 (67%)                     | 2/5 (40%)                | 1        |
| Antinuclear antibody (N=11)                                 | _                             | 5/11 (46%)                 | 1/2 (50%)                     | 4/9 (44%)                | 1        |

N is the total number of patients with available data, and n the number of positive patients.
Table 3: Cerebrospinal fluid analysis

| CSF analysis: data are n/N (%) | Normal range | All patients (n=37) | Non-hemorrhagic forms (n=17) | Hemorrhagic forms (n=20) | p-values |
|--------------------------------|--------------|---------------------|-------------------------------|--------------------------|----------|
| Markers of inflammation (N=31) | -            | 21/31 (68%)         | 10/16 (63%)                  | 11/15 (73%)              | 0.7      |
| High white blood cell count (N=31) | < 5/mm³ | 14/31 (45%)        | 8/16 (50%)                   | 6/15 (40%)               | 0.72     |
| Low glycorrhachia (N=31) | > 50% of the concentration of blood glucose | 0 | - | - | - |
| High proteinorachia (N=31) | (0.15–0.45g/L) | 11/31 (36%) | 6/16 (38%) | 5/15 (33%) | 1 |
| Elevated Immunoglobulin G (N=16) | (10–34mg/L) | 7/16 (44%) | 3/6 (50%) | 4/10 (40%) | 1 |
| Presence of oligoclonal IgG bands with the same pattern in serum (N=13) | - | 6/13 (46%) | 1/4 (25%) | 5/9 (56%) | 0.55 |
| Positive RT-PCR SARS-CoV-2 (N=28) | - | 1/28 (4%) | 1/14 (7%) | 0/14 (0%) | 1 |
| High Interleukin-6 (N=6) | (0–13pg/mL) | 2/6 (33%) | 0/1 (0%) | 2/5 (40%) | 1 |
| High Interleukin-10 (N=6) | (0–3pg/mL) | 1/6 (17%) | 1/1 (100%) | 0/5 (0%) | 0.16 |

N is the total number of patients with available data, and n the number of positive patients.
190 consecutive COVID-19 patients with neurologic manifestations who performed a brain MRI were included in 16 French hospitals from March 23 to April 27, 2020.

Excluded: all patients with normal brain MRIs, ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event.

37 patients with confirmed brain MRI parenchymal signal abnormalities were included. 33 (89%) performed brain MRI with contrast agents.

Neuroimaging findings:
- 16 (43%) unilateral FLAIR and/or diffusion hyperintensities located in mesial temporal lobe;
- 11 (30%) non-confluent multifocal white matter hyperintense lesions on FLAIR/diffusion, with variable enhancement, associated with hemorrhagic lesions;
- 9 (24%) extensive and isolated white matter microhemorrhages;
- 4 (11%) extensive and confluent supratentorial white matter FLAIR hyperintensities;
- 2 (5%) FLAIR and diffusion ovoid hyperintense lesion located in the central part of the splenium of the corpus callosum;
- 2 (5%) non-confluent multifocal white matter hyperintense lesions on FLAIR/diffusion, with variable enhancement;
- 2 (5%) acute necrotizing encephalopathy;
- 2 (5%) FLAIR or diffusion hyperintense lesions involving both middle cerebellar peduncles.

28 (76%) patients were associated with one neuroimaging pattern, 7 (19%) with two patterns, and 2 (6%) showed three patterns.

Figure 1. Flowchart of patient inclusion and exclusion.
Figure 2. Axial FLAIR in four different COVID-19 patients. A) 58-year old man with impaired consciousness: FLAIR hyperintensities located in the left medial temporal lobe. B) 66-year old man with impaired consciousness: FLAIR ovoid hyperintense lesion located in the central part of the splenium of the corpus callosum. C) 71-year old woman with pathological wakefulness after sedation: extensive and confluent supratentorial white matter FLAIR hyperintensities (arrows). Association with leptomeningeal enhancement (stars) D) 61-year old man with confusion: hyperintense lesions involving both middle cerebellar peduncles.
Figure 3. 65-year old man with pathological wakefulness after sedation. Non-confluent multifocal white matter hyperintense lesions on FLAIR and diffusion, with variable enhancement, and hemorrhagic lesions. Axial Diffusion (A, B), Apparent Diffusion Coefficient (ADC) map (C), axial FLAIR (D, E), sagittal FLAIR (F), axial Susceptibility weighted imaging (SWI) (G), and postcontrast T1 weighted MR images (H). Multiple nodular hyperintense Diffusion and FLAIR lesions localized in the white matter including the corpus callosum (F). Some of them (white arrow) are associated with reduced ADC corresponding to cytotoxic edema (C). Other lesions are located next to the lenticular nucleus (cross) (E, G, H), with hemorrhagic changes (G), and enhancement after contrast administration.
**Figure 4.** 57-year old man with pathological wakefulness after sedation. Extensive and isolated white matter microhemorrhages. Axial Susceptibility weighted imaging (SWI) (A, B, C, D): multiple microhemorrhages mainly affecting the subcortical white matter, corpus callosum, internal capsule, and cerebellar peduncles.
Figure 5. 54-year old man with pathological wakefulness after sedation. Non-confluent multifocal white matter hyperintense lesions on FLAIR and diffusion, with variable enhancement. Axial Diffusion (A, B), Apparent Diffusion Coefficient (ADC) map (C, D), axial postcontrast FLAIR (E, F), and postcontrast T1 weighted MR images (G, H). Multiple nodular hyperintense Diffusion and FLAIR subcortical and corticospinal tracts lesions, with very mild mass effect on adjacent structures. The lesions present a center with an elevation of ADC corresponding to vasogenic edema and a peripheral ring of reduced ADC corresponding to cytotoxic edema (C, D). After contrast administration, small areas of very mild enhancement are detected (G, H).
Figure 6. 51-year old man with impaired consciousness. Acute necrotizing encephalopathy. Axial FLAIR (A, C, D), and coronal FLAIR (B): bilateral FLAIR hyperintensity (cross) in both thalami (A, B), associated with involvement of the cerebellar (C), and cerebral (D) white matter (arrows).